In recent weeks, stories about the dangers and difficulties of developing and testing innovative therapies have been in the news. In one national story, a 19 year-old girl committed suicide during the testing of an anti-depressant drug. Another recent article reported that biotechnology companies are moving away from the risky business of developing new technologies and instead are licensing drugs that are already on the market, in part because of complex federal regulations. These stories underscore the tension between two equally important goals: protecting the rights and health of citizens and creating a favorable environment for the aggressive development of life-saving drugs and vaccines.
On March 12, 2004, from 8:30 a.m.–4:30 p.m., Brooklyn Law School's Center for Health Law and Policy and The New York Academy of Medicine will co-host a symposium exploring the necessity and dangers inherent in "Developing Innovative Therapies in a Complex Regulatory Environment." The daylong program will explore regulation of innovative therapies from a variety of perspectives--medical, legal, ethical and economic.
The symposium will provide opportunities for a dynamic dialogue among some of the most knowledgeable experts in the field. Among the participants are: Alan R. Fleischman, M.D., Senior Vice President of The New York Academy of Medicine, Dr. Michael A. Carome, Associate Director for Regulatory Affairs, Office for Human Research Protections (OHRP), Joanne E. Pollak, Vice President and General Counsel, Johns Hopkins Medicine, and M. Gregg Bloche, M.D., J.D., Professor of Law at Georgetown University and Adjunct Professor at Johns Hopkins University, Bloomberg School of Public Health.
Source: Eurekalert & othersLast reviewed: By John M. Grohol, Psy.D. on 21 Feb 2009
Published on PsychCentral.com. All rights reserved.
I am always doing that which I can not do, in order that I may learn how to do it.
-- Pablo Picasso